Why the study?
Does 3.2% versus 3.8% sodium citrate concentration affect anti-Xa levels in patients on therapeutic low molecular weight heparin?
Does 3.2% versus 3.8% sodium citrate concentration affect anti-Xa levels in patients on therapeutic low molecular weight heparin?
Different sodium citrate concentrations (3.2% vs 3.8%) yield statistically equivalent anti-Xa levels for patients on dalteparin, supporting the exclusive use of 3.2% to standardize coagulation testing.
No impact on anti-Xa monitoring from citrate choice; leaves open standardization to 3.2% without higher-level confirmation.
In this study, we compared the effect of sodium citrate, a sample collection variable, on the anti-Xa levels of patients (n = 28) on dalteparin, a low molecular weight heparin. The median anti-Xa level for 3.2% sodium citrate was 0.235 U/ml while the median level for 3.8% sodium citrate was 0.230 U/ml. We conclude that different sodium citrate concentrations give statistically equivalent anti-Xa levels for the same samples. This conclusion is in contrast to the findings of the effect of sodium citrate concentration on International Normalized Ratio (INR) and activated partial-thromboplastin time (aPTT). In accordance with previous recommendations, we advocate the exclusive use of 3.2% sodium citrate in an effort to standardize coagulation testing.
No takes yet. Share an insight, caveat, or question.
Payne et al. (2003) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: